Welcome to our dedicated page for ACCENDRA HEALTH INC/VA/ SEC filings (Ticker: OMI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ACCENDRA HEALTH INC/VA/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ACCENDRA HEALTH INC/VA/'s regulatory disclosures and financial reporting.
Accendra Health, Inc. has launched exchange offers and related consent solicitations for its outstanding 4.500% Senior Notes due 2029 and 6.625% Senior Notes due 2030. Eligible holders can swap these unsecured notes into newly issued 9.000% senior secured first lien notes due 2032 and 9.750% senior secured second lien notes due 2033, with different consideration levels depending on participation in a new money notes issuance and early tender deadlines. The company is also raising $326.25 million in new first lien notes for cash and seeking consents to strip most covenants and certain events of default from the existing indentures. Accendra notes the offers are subject to multiple conditions and warns that failing to complete these or alternative transactions on favorable terms could materially adversely affect its financial condition.
Accendra Health EVP and General Counsel Heath H. Galloway reported a routine tax-related share disposition. On May 18, 2026, 1,822 shares of Accendra Health common stock were surrendered at $2.91 per share to cover tax withholding tied to vesting of restricted stock.
These shares were delivered back to the company rather than sold in the open market. After this transaction, Galloway directly holds 166,306 shares of Accendra Health common stock, showing he retains a substantial equity stake following the tax withholding event.
Accendra Health EVP & CFO Jonathan A. Leon reported a small share disposition related to taxes rather than an open-market trade. On May 15, 2026, he surrendered 1,770 shares of Common Stock at $3.04 per share to cover tax withholding tied to vesting of restricted stock. After this tax-withholding transaction, he directly held 290,533 shares of Accendra Health common stock.
Accendra Health President and CEO Edward A. Pesicka surrendered 17,692 shares of common stock on May 15, 2026 to cover tax withholding obligations tied to vesting of restricted stock. These shares were delivered back to the company rather than sold on the open market. Following this routine tax-withholding disposition, he directly holds 1,072,785 common shares.
Accendra Health Inc. executive Heath H. Galloway reported a routine tax-related share disposition. On this Form 4, 966 shares of common stock were surrendered to the company at $3.04 per share to cover tax withholding tied to vesting of restricted stock. After this non-market transaction, Galloway directly holds 168,128 common shares.
Kline Teresa L. reported acquisition or exercise transactions in this Form 4 filing.
Accendra Health Inc. director Teresa L. Kline received a grant of 31,191 shares of common stock as equity compensation. The shares were awarded at no cash cost to her and are structured as restricted stock. Following this grant, she directly holds 85,316 common shares.
The restricted stock grant will vest on the earlier of one year from the grant date or the date of the next annual meeting that occurs at least 50 weeks after the grant date, aligning the director’s compensation with shareholder interests over that period.
Klemash Stephen W reported acquisition or exercise transactions in this Form 4 filing.
ACCENDRA HEALTH INC/VA/ director Stephen W. Klemash received a grant of 31,191 shares of Common Stock as a restricted stock award. The grant was awarded at a price of $0.00 per share as part of equity compensation and increased his directly held shares to 90,242.
The restricted stock will vest on the earlier of one year from the grant date or the date of the next annual meeting that is at least 50 weeks after the grant date. This is a compensation-related equity grant rather than an open-market share purchase.
Gardner-Smith Kenneth reported acquisition or exercise transactions in this Form 4 filing.
Accendra Health Inc. director Kenneth Gardner-Smith received a grant of 31,191 shares of Common Stock as restricted stock on May 14, 2026. These shares were awarded at no cash cost and increase his direct holdings to 86,113 shares.
The restricted stock grant vests on the earlier of one year from the grant date or the next annual meeting that is at least 50 weeks after the grant date, meaning the award is tied to continued board service over roughly a one-year period.
Bingham Gwendolyn M reported acquisition or exercise transactions in this Form 4 filing.
Accendra Health director Gwendolyn M. Bingham received a grant of 31,191 phantom stock units on May 14, 2026 at no cost. This award increases her phantom stock holdings to 80,603 units. Each phantom unit is convertible on a 1-for-1 basis into common stock and becomes payable, in cash or common stock at her election, upon events such as death, disability, termination of service as director, or a preselected future delivery date.
Beck Mark A reported acquisition or exercise transactions in this Form 4 filing.
Accendra Health Inc. director Mark A. Beck received a grant of 31,191 shares of common stock as equity compensation. The restricted stock was awarded at no cash cost to him and increases his direct holdings to 71,259 shares.
According to the terms, the restricted stock vests on the earlier of one year from the grant date or the date of the next annual meeting that is at least 50 weeks after the grant date. Until vesting, these shares are subject to forfeiture conditions typically linked to continued board service.